【摘要】 新型冠状病毒肺炎(COVID-19)是一种由严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)所致的传染病，自2019年末以来在全球迅速传播。当前科学界正进行前所未有的努力，研究该病毒感染的潜在机制并提出合理的临床应用药物，以降低COVID-19发病率。法匹拉韦(favipiravir)是一种RNA依赖性RNA聚合酶(RdRp)抑制剂，在中国被批准用于治疗COVID-19。该文概述法匹拉韦通过结合SARS-CoV-2 3种关键病毒酶RdRp、3-胰凝乳蛋白酶样半胱氨酸蛋白酶(3CLpro)和木瓜蛋白酶样蛋白酶(PLpro)抑制SARS-CoV-2的机制，并综述法匹拉韦与上述病毒蛋白酶的分子对接数据。更多还原

【Abstract】 Corona virus disease 2019（COVID-19）,as an infectious disease caused by severe acute respiratory syndrome coronavirus type 2（SARS-CoV-2）,spread rapidly across the world at the end of 2019.The rapid spread of COVID-19 has also prompted the scientific community to make unprecedented efforts to study the potential mechanism of viral infection and propose reasonable clinical applications to reduce the incidence of COVID-19.Favipiravir, an RNA-dependent RNA polymerase（RdRp） inhibitor, is approved in China for the treatment of COVID-19.This article outlines that favipiravir inhibits SARS-CoV-2 by binding to three key viral enzymes of SARS-CoV-2,RdRp, 3-chymotrypsin-like protease(3 CL^pro),and Papain-like-protease(PL^pro).And this paper reviewed the data of the molecular docking of favipiravir and the above-mentioned viral proteases of SARS-CoV-2.更多还原